Mountain View, Calif.– Materna Medical, a women’s health company focused on pelvic health innovations, has announced an additional close in its ongoing $20 million Series B2 funding round. The latest funding brings in new investors GLIN Impact Capital, Wealthing VC Club, and Citrine Angels, joining lead investor InnovaHealth Partners and returning backers including Wavemaker Three-Sixty Health, Kimera Limited, Women’s Venture Capital Fund, and Golden Seeds.
Alongside the funding update, the company also revealed the commercial name for its second product: Ellora™, formerly known as Materna Prep. The device is designed to improve outcomes in labor and delivery and is currently under evaluation in the EASE trial, being conducted in collaboration with more than 20 leading U.S. hospitals. Results from the study will support Materna’s planned FDA De Novo submission later this summer.
“As we celebrate the addition of these new funds to our investment team, we are also excited to announce the new commercial name for our second product, Ellora™,” said Tracy MacNeal, CEO of Materna Medical. “Our partners in the EASE trial have been instrumental in helping us advance this solution, which we believe can redefine the standard of care in childbirth.”
The expanded funding and upcoming regulatory submission mark key milestones as the company continues to build momentum in the women’s health space.
